Drug Trial Radar · NCT06771622
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Mar 13, 2025
Primary completion
Jan 1, 2028
Study completion Jan 1, 2029
Sponsor
- Lead sponsor
- FBD Biologics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-randomized, open-label, dose-escalation, and dose-expansion Phase Ib/IIa study to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of HCB101 administered in combination with standard or approved anticancer therapies in subjects with advanced solid tumors. The trial includes a Part-I (Phase Ib) of the dose-escalation phase and a Part-II (Phase IIa) of the dose-expansion phase. Part-I: Dose-escalation phase (Phase Ib): Part I uses a standard 3+3 dose-escalation design to characterize safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of HCB101 when administered in combination regimens. The study includes 14 planned cohorts (Cohorts 1-9, including sub-cohorts 3a-3d and 6a-6c). Part-II: Dose-expansion phase (Phase IIa) Based on safety, tolerability, PK/PD, and emerging antitumor activity observed in Part-I (Phase Ib), selected dose levels, tumor types, and combination regimens will be further investigated in Part-II (Phase IIa).
Conditions
- Solid Cancer
Interventions
HCB101Drug
QW
TrastuzumabDrug
8 mg/kg IV loading dose on Day 1 of cycle 1, then 6 mg/kg IV every 21 days;
PertuzumabDrug
840 mg IV on Day 1, cycled every 21 days;
OxaliplatinDrug
130 mg/m2 IV on Day 1, cycled every 21 days
CapecitabineDrug
1000 mg/m2 PO BID on Days 1-14, Cycled every 21 days
RamucirumabDrug
8 mg/kg IV on Days 1 and 15, Cycled every 28 days
PaclitaxelDrug
80 mg/m2 IV on Days 1, 8, and 15, Cycled every 28 days
BevacizumabDrug
5 mg/kg IV on Day 1, Repeat every 2 weeks;
CetuximabDrug
400 mg/m2 first infusion, followed by 250 mg/m2 IV weekly;
IrinotecanDrug
180 mg/m2 IV over 30-90 minutes on Day 1 every 2 weeks
LeucovorinDrug
400 mg/m2 IV on Day 1 every 2 weeks
5-FUDrug
400 mg/ m2 IV bolus on Day 1, followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks
ToripalimabDrug
240 mg/kg IV on Day 1 Cycled every 21 days
Albumin-bound paclitaxelDrug
125 mg/m2 IV on day 1 and Day 8 Cycled every 21 days
PembrolizumabDrug
200 mg IV day 1; given every 21 days
Carboplatin (AUC 5)Drug
AUC=5, IV on D1, Q3W for 4\~6 cycles
EtoposideDrug
100mg/m2, IV on D1, 2, 3, Q3W for 4\~6 cycles
AtezolizumabDrug
1200 mg IV on D1, Q3W
Trastuzumab deruxtecanDrug
5.4 mg/kg IV on D1, Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number/incidence and percentage of subjects with adverse events.Time frame: 12 months
- Number of subjects with Maximal tolerance dose (MTD) of HCB101Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.